Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preparation method of human blood coagulation factor VIII and human blood coagulation factor VIII product

A technology of human blood coagulation factor and cryoprecipitation, which is applied to the preparation method of factor VII, peptide, coagulation/fibrinolysis factor, etc. It can solve the problems of low specific activity, low yield, and failure to meet the basic medication needs of patients.

Active Publication Date: 2018-04-06
HUALAN BIOLOGICAL ENG INC +2
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are only a few companies in China that have the production approval of AHF, and the supply is seriously in short supply, unable to meet the basic drug needs of patients
The existing AHF is mainly prepared by methods such as polyethylene glycol precipitation and aluminum hydroxide adsorption, which have disadvantages such as low specific activity and low yield. Facing the current situation of insufficient supply in the domestic AHF market, it is necessary to develop a high-yield, relatively low-yield Hogao's AHF preparation method has positive significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of human blood coagulation factor VIII and human blood coagulation factor VIII product
  • Preparation method of human blood coagulation factor VIII and human blood coagulation factor VIII product
  • Preparation method of human blood coagulation factor VIII and human blood coagulation factor VIII product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] The method for preparing human coagulation factor VIII provided in this embodiment includes the following steps:

[0070] 1. Steps for collecting raw plasma:

[0071] 1.1 The collection and quality of plasma should comply with the provisions of "Human Plasma for the Production of Blood Products" in the current edition of the Pharmacopoeia of the People's Republic of China. It should be frozen within 4 hours after collection and stored at -30°C for no more than 1 year.

[0072] 1.2 The plasma should have no clots, no fibrin precipitation, no lipemia, and no hemolysis.

[0073] 2. Cryogenic precipitation preparation steps:

[0074] Weigh 2097kg of frozen plasma (total 3495 human plasma), soak or wipe the surface with 70% ethanol solution (the ethanol solution is required to control 70%-75%), then break the bag and combine it into the tank. Melt in a water bath, and control the melting temperature at 4°C (control the melting temperature at 0-4°C).

[0075] Use a low-temperature high...

Embodiment 2

[0107] The method for preparing human coagulation factor VIII provided in this embodiment is basically the same as that in Embodiment 1, except that in this embodiment:

[0108] The balance solution contains: tromethamine 18mmol / L, sodium chloride 90mmol / L, glycine 110mmol / L and calcium chloride 38μmol / L.

[0109] The dialysate contains: sodium nitrate 11mmol / L, histidine 28mmol / L, glycine 130mmol / L and calcium chloride 1.1mmol / L.

Embodiment 3

[0111] The method for preparing human coagulation factor VIII provided in this embodiment is basically the same as that in Embodiment 1, except that in this embodiment:

[0112] The balance solution contains: tromethamine 22mmol / L, sodium chloride 110mmol / L, glycine 130mmol / L, and calcium chloride 42μmol / L.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of a human blood coagulation factor VIII and a human blood coagulation factor VIII product and relates to the field of blood products. The preparation method of the human blood coagulation factor VIII comprises the following steps: dissolving a cryoprecipitate with a 0.015-0.025mol / L tromethamine solution in a mass ratio of (3-5): 1 by reasonably processing the cryoprecipitate; and carrying out separation and purification by means of a polyethylene glycol precipitating method combined with ion exchange chromatography, wherein the recovery ratio of the human blood coagulation factor VIII and the specific activity of a final product can be improved effectively, the yield reaches 180-240IU / L plasma, and the specific activity is not lower than 100IU / mg proteins. The prepared human blood coagulation factor VIII product is rich in vWF factors and the proportion of the vWF factors and the human blood coagulation factor VIII is close to 1: 1. Besides treating hemophiliac A, the human blood coagulation factor VIII can be also used for treating patients with angiohemophilia, and the human blood coagulation factor VIII has good stability and heat resistance.

Description

Technical field [0001] The present invention relates to the field of blood products, in particular to a method for preparing human coagulation factor VIII and a human coagulation factor VIII product. Background technique [0002] Human Cogulation Factor VIII (Human Cogulation Factor VIII, AHF) has a corrective effect on the coagulation dysfunction caused by the lack of human coagulation factor VIII. It is a lifelong medication for patients with hemophilia A and a rescue medication for emergency patients. Among the nearly 400,000 hemophilia A patients in the world, there are about 60,000 to 100,000 patients in my country, but only about 8,000 people are receiving treatment. From increasing the treatment rate of hemophilia A patients and guaranteeing emergency medication, The domestic human coagulation factor VIII gap is about 20 times the current output. At present, there are only a few domestic companies with AHF production approval, and the supply is severely in short supply, un...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/755C07K1/36C07K1/34C07K1/30C07K1/18C07K1/16
CPCC07K14/755
Inventor 马小伟张宝献范蓓潘若文梁雪爽张学成
Owner HUALAN BIOLOGICAL ENG INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com